Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?

Neuro-Oncology

Volumn 13, Issue 1, 2011, Pages 3-13

  Heimberger, Amy B ^a   Sampson, John H ^b,c,d  

^a UNIVERSITY OF TEXAS   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d DUKE UNIVERSITY   (United States)

Author keywords

Clinical trial; Glioblastoma multiforme; Immunotherapy; Malignant gliomas

Indexed keywords

CARBOXYMETHYLCELLULOSE; CD3 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KEYHOLE LIMPET HEMOCYANIN; PEPTIDE VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; POLYLYSINE; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA2;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NEUROIMMUNOLOGY; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR CELL;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; STANDARD OF CARE;

EID: 79951641692     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq169     Document Type: Review

References (138)

1. Medawar PB. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29:58-69.
2. Fabry Z, Raine CS, Hart MN. Nervous tissue as an immune compartment: the d (Pubitemid 24137975)
3. Parney IF, Hao C, Petruk KC. Glioma immunology and immunotherapy. Neurosurgery. 2000;46:778-791; discussion 791-792.
4. Cserr HF, Knopf PM. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today. 1992;13:507-512.
5. Cserr HF, Harling-Berg CJ, Knopf PM. Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol. 1992;2:269-276.
6. Harling-Berg CJ, Park TJ, Knopf PM. Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation. J Neuroimmunol. 1999;101:111-127. (Pubitemid 29516453)
7. Weller RO, Engelhardt B, Phillips MJ. Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol. 1996;6:275-288. (Pubitemid 26246383)
8. Harling-Berg C, Knopf PM, Merriam J, Cserr HF. Role of cervical lymph nodes in the systemic humoral immune response to human serum albumin microinfused into rat cerebrospinal fluid. J Neuroimmunol. 1989;25:185-193. (Pubitemid 19276908)
9. Harling-Berg CJ, Hallett JJ, Park JT, Knopf PM. Hierarchy of immune responses to antigen in the normal brain. Curr Top Microbiol Immunol. 2002;265:1-22. (Pubitemid 34241976)
10. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-173. (Pubitemid 19138011)
11. Bullard DE, Gillespie GY, Mahaley MS, Bigner DD. Immunobiology of human gliomas. Semin Oncol. 1986;13:94-109. (Pubitemid 16116044)
12. Owens T, Renno T, Taupin V, Krakowski M. Inflammatory cytokines in the brain: does the CNS shape immune responses? Immunol Today. 1994;15:566-571. (Pubitemid 24353907)
13. Stevens A, Kloter I, Roggendorf W. Inflammatory infiltrates and natural killer cell presence in human brain tumors. Cancer. 1988;61:738-743. (Pubitemid 18037925)
14. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res. 1991;28:254-260.
15. Goldmann J, Kwidzinski E, Brandt C, Mahlo J, Richter D, Bechmann I. T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leukoc Biol. 2006;80:797-801. (Pubitemid 44835898)
16. Masson F, Calzascia T, Di Berardino-Besson W, De Tribolet N, Dietrich PY, Walker PR. Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol. 2007;179:845-853.
17. Aloisi F, Ria F, Adorini L. Regulation of T-cell responses by CNS antigenpresenting cells: different roles for microglia and astrocytes. Immunol Today. 2000;21:141-147.
18. Irani DN, Lin KI, Griffin DE. Regulation of brain-derived Tcells during acute central nervous system inflammation. J Immunol. 1997;158:2318-2326. (Pubitemid 127470017)
19. Gehrmann J, Banati RB, Wiessner C, Hossmann KA, Kreutzberg GW. Reactive microglia in cerebral ischaemia: an early mediator of tissue damage? Neuropathol Appl Neurobiol. 1995;21:277-289.
20. Serot JM, Foliguet B, Bene MC, Faure GC. Ultrastructural and immunohistological evidence for dendritic-like cells within human choroid plexus epithelium. Neuroreport. 1997;8:1995-1998. (Pubitemid 27314323)
21. McMenamin PG, Forrester JV. Dendritic cells in the central nervous system and eye and their associated supporting tissues. In: Dendritic Cells: Biology and Clinical Applications. New York: Academic Press; 1999:205-248.
22. Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived andpresentantigeninvivo. Science. 1988;239:290-292. (Pubitemid 18061496)
23. Lowe J, MacLennan KA, Powe DG, Pound JD, Palmer JB. Microglial cells in human brain have phenotypic characteristics related to possible function as dendritic antigen presenting cells. J Pathol. 1989;159:143-149. (Pubitemid 19257232)
24. Ulvestad E, Williams K, Bjerkvig R, Tiekotter K, Antel J, Matre R. Human microglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen-presenting cells. J Leukoc Biol. 1994;56:732-740.
25. Gehrmann J, Banati RB, Kreutzberg GW. Microglia in the immune surveillance of the brain: human microglia constitutively express HLA-DR molecules. J Neuroimmunol. 1993;48:189-198. (Pubitemid 24010174)
26. Williams K, Jr, Ulvestad E, Cragg L, Blain M, Antel JP. Induction ofprimary T cell responses by human glial cells. J Neurosci Res. 1993;36:382-390. (Pubitemid 23326318)
27. Furr M. Antigen-specific antibodies in cerebrospinal fluid after intramuscular injection of ovalbumin in horses. J Vet Intern Med. 2002;16:588-592. (Pubitemid 135747440)
28. Gigliotti F, Lee D, Insel RA, Scheld WM. IgG penetration into the cerebrospinal fluid in a rabbit model of meningitis. J Infect Dis. 1987;156:394-398. (Pubitemid 17098210)
29. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000;18:2349-2351.
30. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2007;18:23-28. (Pubitemid 44949792)
31. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991;49:650-655.
32. Pestalozzi BC. Brain metastases and subtypes of breast cancer. Ann Oncol. 2009;20:803-805.
33. De Vries E. Molecular Imaging of Breast Cancer Paper presented at: 11th International Conference, St. Gallen, Switzerland, 2009.
34. Dey M, Hussain SF, Heimberger AB. The role of glioma microenvironment in immune modulation: potential targets for intervention. Lett Drug Des Discov. 2006;3:443-451.
35. Calzascia T, Masson F, Di Berardino-Besson W, et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity. 2005;22:175-184. (Pubitemid 40255709)
36. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neurooncology. 2006;8:261-279. (Pubitemid 46542651)
37. Platten M, Wick W, Weller M. Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech. 2001;52:401-410. (Pubitemid 32167828)
38. Roszman T, Elliott L, Brooks W. Modulation of T-cell function by gliomas [Review]. Immunol Today. 1991;12:370-374.
39. Tada M, Suzuki K, Yamakawa Y, et al. Human glioblastoma cells produce 77 amino acid interleukin-8 (IL-8(77)). J Neurooncol. 1993;16:25-34. (Pubitemid 23223539)
40. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150-4166. (Pubitemid 28544331)
41. Tirapu I, Huarte E, Guiducci C, et al. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res. 2006;66:2442-2450.
42. Voigt H, Schrama D, Eggert AO, et al. CD28-mediated costimulation impacts on the differentiation of DC vaccination-induced T cell responses. Clin Exp Immunol. 2006;143:93-102.
43. Yi-qun Z, Lorre K, De Boer M, Ceuppens JL. B7-blocking agents, alone or in combination with cyclosporin A, induce antigen-specific anergy of human memory T cells. J Immunol. 1997;158:4734-4740. (Pubitemid 127483793)
44. Matyszak MK, Denis-Donini S, Citterio S, Longhi R, Granucci F, Ricciardi-Castagnoli P. Microglia induce myelin basic protein-specific T cell anergy or T cell activation, according to their state of activation. Eur J Immunol. 1999;29:3063-3076. (Pubitemid 29484196)
45. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13:84-88. (Pubitemid 46067390)
46. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother. 2005;28:582-592. (Pubitemid 41533092)
47. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res. 1987;47:3317-3321. (Pubitemid 17082667)
48. Foss F. Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006;33:11-16.
49. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-562. (Pubitemid 38680433)
50. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004;22:610-616. (Pubitemid 41095063)
51. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949. (Pubitemid 39273735)
52. El Andaloussi A, Lesniak MS. CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol. 2007;83:145-152. (Pubitemid 46784987)
53. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66:3294-3302.
54. Heimberger AB, Reina-Ortiz C, Yang DS, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008;14:5166-5172.
55. Umemura N, Saio M, Suwa T, et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1-and M2-type characteristics. J Leukoc Biol. 2008;83:1136-1144. (Pubitemid 351960345)
56. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol. 2009;70:325-330.
57. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71-78. (Pubitemid 38082155)
58. Di Tomaso T, Mazzoleni S, Wang E, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res. 2010;16:800-813.
59. Schatton T, Schutte U, Frank NY, et al. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res. 2010;70:697-708.
60. Wei J, Bar J, Kong L-Y, et al. Glioblastoma cancer-initiating cells inhibit T cell proliferation and effector responses by the STAT3 pathway. Mol Cancer Ther. 2010;9:67-78.
61. Wei J, Barr J, Kong L-Y, et al. Glioma associated cancer-initiating cells induce immune suppression. Clin Cancer Res. 2010;16:461-473.
62. Brown CE, Starr R, Martinez C, et al. Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells. Cancer Res. 2009;69:8886-8893.
63. Pellegatta S, Finocchiaro G. Dendritic cell vaccines for cancer stem cells. Methods Mol Biol. 2009;568:233-247.
64. Xu Q, Liu G, Yuan X, et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells. 2009;27:1734-1740.
65. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ. Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol. 2002;169:2253-2263. (Pubitemid 34920965)
66. O'Farrell AM, Liu Y, Moore KW, Mui AL. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and independent pathways. EMBO. J. 1998;17:1006-1018. (Pubitemid 28077655)
67. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity. 1999;10:39-49. (Pubitemid 29077382)
68. Lin T, Bost K. STAT3 activation in macrophages following infection with Salmonella. Biochem Biophys Res Commun. 2004;321:828-834. (Pubitemid 39044385)
69. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11:1314-1321. (Pubitemid 41752912)
70. Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010;12:1113-1125.
71. Kong L-K, Wei J, Sharma AK, et al. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother. 2008;58:1023-1032.
72. Kong LY, Abou-Ghazal MK, Wei J, et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res. 2008;14:5759-5768.
73. Zorn E, Nelson EA, Mohseni M, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006;108:1571-1579. (Pubitemid 44316124)
74. Zhang JG, Kruse CA, Driggers L, et al. Tumor antigen precursor protein profiles of adult and pediatric brain tumors identifies potential targets for immunotherapy. J Neuro-Oncol. 2008;88:65-76.
75. He XS, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol. 2006;80:11756-11766. (Pubitemid 44788888)
76. Postel-Vinay S, Arkenau HT, Olmos D, et al. Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer. 2009;100:1373-1378.
77. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018-1028. (Pubitemid 44343545)
78. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
79. Rhee DJ, Kong DS, Kim WS, et al. Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas. Clin Neurol Neurosurg. 2009;111:748-751.
80. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16:2443-2449.
81. Shahar T, Nossek E, Blumenthal DT, et al. Trial to survive: the impact of enrollment in clinical trials on survival of patients with glioblastoma. Neurosurgery. 2009;65:425.
82. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670-1677. (Pubitemid 38435557)
83. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6(suppl 1): S11-S14.
84. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116. (Pubitemid 29318842)
85. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using highdose bolus interleukin 2. JAMA. 1994;271:907-913.
86. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-3094. (Pubitemid 46638945)
87. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
88. El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neurooncology. 2006;8:234-243. (Pubitemid 46542648)
89. Fecci PE, Sweeney AE, Grossi PM, et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res. 2006;12:4294-4305.
90. Carro MS, Lim WK, Alvarez MJ, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010;463:318-325.
91. Freije WA, Castro-Vargas FE, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004;64:6503-6510. (Pubitemid 39297907)
92. Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26:3015-3024.
93. Murat A, Migliavacca E, Hussain SF, et al. Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One. 2009;4: e5947.
94. Hoover HC, Jr, Surdyke M, Dangel RB, Peters LC, Hanna MG, Jr. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guerin vaccine. Cancer Res. 1984;44:1671-1676. (Pubitemid 14125862)
95. Khleif SN, Abrams SI, Hamilton JM, et al. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother. 1999;22:155-165. (Pubitemid 29135900)
96. Maraveyas A, Baban B, Kennard D, et al. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol. 1999;10:817-824. (Pubitemid 29367999)
97. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999;80:219-230. (Pubitemid 29001725)
98. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332. (Pubitemid 28144092)
99. Reynolds SR, Oratz R, Shapiro RL, et al. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer. 1997;72:972-976. (Pubitemid 27433560)
100. Schreiber S, Kampgen E, Wagner E, et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Hum Gene Ther. 1999;10:983-993. (Pubitemid 29195428)
101. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107:4781-4789. (Pubitemid 43882629)
102. Lindenstrom T, Agger EM, Korsholm KS, et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol. 2009;182:8047-8055.
103. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8:247-258. (Pubitemid 351432801)
104. Betts MR, Exley B, Price DA, et al. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci USA. 2005;102:4512-4517. (Pubitemid 40397143)
105. Betts MR, Gray CM, Cox JH, Ferrari G. Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development. Expert Rev Vaccines. 2006;5:505-516. (Pubitemid 44627882)
106. Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, et al. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med. 2009;206:849-866.
107. Yuan J, Gnjatic S, Li H, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA. 2008;105:20410-20415.
108. Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008;68:5955-5964.
109. Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009;8:2773-2779.
110. Boasberg PD, Hoon DS, Piro LD, et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol. 2006;126:2658-2663. (Pubitemid 44764050)
111. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709-718. (Pubitemid 43247141)
112. Kaehler KC, Egberts F, Lorigan P, Hauschild A. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. Melanoma Res. 2009;19:333-334.
113. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46-54. (Pubitemid 36818745)
114. Wikstrand CJ, Bigner DD. Hyperimmunization of non-human primates with BCG-CW and cultured human glioma-derived cells. Production of reactive antisera and absence of EAE induction. J Neuroimmunol. 1981;1:249-260. (Pubitemid 11024451)
115. Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003;9:4247-4254. (Pubitemid 37204046)
116. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8:959-968.
117. PRNewswire, vol. 2010. 2006.
118. Nundy S, Gulhati CM. A new colonialism?-conducting clinical trials in India. N Engl J Med. 2005;352:1633-1636. (Pubitemid 40530229)
119. O'Reilly KB. Outsourcing clinical trials: is it ethical to take drug studies abroad. 2009 [cited 2010 February 18]; Available from: http://www.ama-assn.org/amednews/2009/09/07/prsa0907.htm
120. Sampson JH, Heimberger AB, Archer G, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:4722-4729.
121. Sampson JH, Archer GE, Bigner DD, et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J Clin Oncol (Meeting Abstracts). 2008;26:2011.
122. Yajima N, Yamanaka R, Mine T, et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res. 2005;11:5900-5911. (Pubitemid 41170319)
123. Mitchell DA, Archer G, Bigner D, et al. RNA-loaded dendritic cells targeting cytomegalovirus in patients with malignant glioma. Neurooncology. 2007;9:509.
124. De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008;14:3098-3104.
125. Yu J, Liu G, Ying H, Yong W, Black K, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64:4973-4979. (Pubitemid 38924545)
126. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11:5515-5525. (Pubitemid 41060828)
127. Fakhrai H, Mantil JC, Liu L, et al. Phase I clinical trial of a TGF-b antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther. 2006;13:1052-1060. (Pubitemid 44760103)
128. Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol. 2009;91:175-182.
129. Sloan AE, Dansey R, Zamorano L, et al. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus. 2000;9: e9.
130. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res. 2000;6:1347-1350. (Pubitemid 30226219)
131. McNeel DG, Schiffman K, Disis ML. Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1999;93:2653-2659. (Pubitemid 29181198)
132. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669-1678. (Pubitemid 30002348)
133. Altman J, Moss P, Goulder P, et al. Phenotypic analysis of antigenspecific T lymphocytes. Science. 1996;274:94-96.
134. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol. 1999;162:2227-2234. (Pubitemid 29288845)
135. Mackensen A, Veelken H, Lahn M, et al. Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts. J Mol Med. 1997;75:290-296. (Pubitemid 27209978)
136. Dunbar PR, Ogg GS, Chen J, Rust N, van der Bruggen P, Cerundolo V. Direct isolation, phenotyping and cloning of low-frequency antigenspecific cytotoxic T lymphocytes from peripheral blood. Curr Biol. 1998;8:413-416. (Pubitemid 28174001)
137. Pittet MJ, Valmori D, Dunbar PR, et al. High frequencies of naive Melan-A/MART-1-specific CD8 (+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med. 1999;190:705-715. (Pubitemid 29428652)
138. Schmittel A, Keilholz U, Scheibenbogen C. Evaluation of the interferongamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods. 1997;210:167-174. (Pubitemid 28266560)